How Much of My Revenue Should Be Left After Supply and Drug Costs in a Procedural Facility?

What remains after supply and drug costs in a physician-owned ASC or OBL is not a fixed number. It varies by procedure mix, case volume, and the commodity supply cost position the facility holds relative to comparable independent facilities. That last variable is the one most physician-owned procedural facilities have never formally evaluated. Two facilities running identical procedures at identical volumes can retain materially different percentages of net revenue after supply and drug costs, and the difference between them is not clinical. It is a purchasing position difference that does not appear in either facility’s standard financial reporting.

What Drives the Variance Between Facilities

Published benchmarks place total supply and drug costs for independent ASCs at approximately 18 to 28 percent of net revenue, with significant variance by specialty mix and case complexity. According to VMG Health’s multi-specialty ASC benchmarking data, the average ASC allocates 26.3 percent of its operating budget to drugs and medical supplies. However, the variance within that figure between facilities at similar volume is material. Facilities at the 25th percentile and those at the 75th percentile of supply cost efficiency retain meaningfully different percentages of net revenue and driven not by clinical differences but by the purchasing position each facility holds relative to its distributor network.

For cardiovascular and vascular OBLs, the picture shifts further. Higher device and implant costs per case increase the total supply and drug cost percentage relative to general surgery ASCs. However, device costs are procedure-specific and largely negotiated at the case level. The commodity supply layer underneath every case, regardless of procedure type, is where the less visible variance resides. Drugs, contrast agents, saline, procedure packs, and consumables reprice on distributor contract cycles that the facility does not control. Each repricing event is incremental. The cumulative movement over time creates a gap between what the facility pays and what comparable independent facilities pay for the same inputs, without producing a clear line item in standard financial reporting.

As examined in prior work on the difference between revenue growth and actual profitability, the percentage of revenue retained after costs is most meaningful when it is measured against a relevant peer comparison rather than against the facility’s own prior periods. A facility whose supply and drug costs have increased consistently over three years may show a stable cost percentage. Against a peer benchmark, that same facility may be retaining significantly less revenue than comparable independent facilities at its volume and specialty mix.

What the Published Range Cannot Tell You

A published benchmark range for supply and drug costs as a percentage of revenue tells a physician-owner where the category sits across a broad population of facilities. It does not tell them where their facility sits within that population, or why.

The distinction that matters is between costs that are above the published range because the facility’s procedure mix genuinely requires it, and costs that are above the range because the facility’s commodity supply cost position has never been tested against what comparable independent facilities pay. These are different conditions. One reflects clinical reality. The other reflects an information gap. And from inside the facility’s own financial reporting, there is no mechanism to tell them apart.

Furthermore, aggregate benchmarks obscure the variance within any given procedure category. The more useful comparison for an independent cardiovascular or vascular OBL is not against an average drawn from multi-specialty ASCs but against independent facilities at similar volume running similar procedures. That comparison requires peer pricing data that has not historically been available to independent operators as a matter of course.

The Number That Answers the Question

The percentage of net revenue remaining after supply and drug costs becomes a decision-making tool only when it is evaluated against the right reference point. For most independent physician-owned ASCs and OBLs, that reference point has never been constructed. The facility knows what percentage it retains. It does not know whether that percentage reflects a competitive cost position or a purchasing structure that has moved above market rates over time.

Those are different answers to the same question. And the only way to know which one applies to your facility is to see your actual commodity supply costs mapped against documented pricing from comparable independent facilities at your volume and specialty mix. That comparison does not exist inside your own reporting. It has not historically been on the independent operator’s side of the table.

If you want to know where your facility’s supply and drug cost position sits relative to peer independent facilities, request your complimentary supply cost analysis at vantumpartners.com. You see your actual cost position against documented market rates. No obligation.

Frequently Asked Questions

How much of my revenue should be left after supply and drug costs in a physician-owned ASC or OBL?

The percentage of net revenue remaining after supply and drug costs varies by procedure mix, case volume, and commodity supply cost position relative to peer independent facilities. Published benchmarks place total supply and drug costs for independent ASCs at approximately 18 to 28 percent of net revenue, though the variance within that range between facilities at similar volume is material. The more relevant question for most independent physician-owned facilities is not where the category average sits but whether their specific cost position reflects market rates for comparable facilities at their volume and specialty mix.

Why do two facilities with the same procedure mix retain different percentages of revenue after supply costs?

Two independent ASCs or OBLs with identical procedure mixes and similar case volumes can retain materially different percentages of net revenue after supply and drug costs because commodity supply pricing varies between facilities based on their respective purchasing positions. Device and implant costs are procedure-specific and partially determined by clinical negotiation. Commodity supply costs reprice inside distributor relationships on contract cycles the facility does not control. The gap between a facility whose commodity supply costs reflect current market rates for comparable independent facilities and one whose costs have moved above market represents a real and measurable difference in per-case profitability that has nothing to do with clinical performance.

What percentage of revenue do supply and drug costs typically represent in an independent ASC?

Published benchmarks place total supply and drug costs for independent ASCs at approximately 18 to 28 percent of net revenue, with significant variance by specialty mix, case complexity, and commodity supply cost position. For cardiovascular and vascular OBLs, higher device and implant costs push the upper end of that range. However, within any procedure mix category, the variance in commodity supply costs between facilities at similar volume can be material. That variance reflects purchasing position differences rather than clinical differences, and it does not surface in aggregate benchmarks.

Does adding more cases improve the percentage of revenue retained after supply and drug costs?

Adding cases increases total revenue and distributes fixed supply expenses across more revenue-generating events, which can improve overall margin ratios. However, if the facility’s commodity supply cost position is above market rates for comparable independent facilities, adding cases compounds that cost gap rather than closing it. Volume growth does not correct a purchasing position that has moved above market rates. The percentage of revenue retained after commodity supply costs reflects the facility’s cost position relative to the market, not its case volume.

How do I know if my supply and drug costs are competitive for my facility type?

Knowing whether your supply and drug costs are competitive requires a comparison that does not exist inside your own financial reporting: your actual invoice-level commodity supply costs measured against what comparable independent facilities at your volume and specialty mix actually pay for the same inputs. Published benchmarks provide a category-level orientation. Your own prior period comparisons confirm whether costs have changed relative to your own history. Neither tells you whether your current cost position reflects market rates or a purchasing structure that has moved above them over time.